Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > LATEST
LATEST
-
COLUMN Maurer's Healthcare Insight (33)
September 2, 2002
-
ARCHIVE FJPWA Asks Korosho to Abolish Recording Lot Numbers
September 2, 2002
-
ARCHIVE Iressa's Price Set by Cost Calculation Method
September 2, 2002
-
ARCHIVE Tempstaff Dispatches 130 CRAs to Over 10 Drug Companies
September 2, 2002
-
ARCHIVE WORLD NEWS IN BRIEF
September 2, 2002
-
ARCHIVE Sankyo Starts e-Promotion
September 2, 2002
-
ARCHIVE Takara Bio: High-Sensitivity DNA Chip Template "Takara-Hubble Slide"
September 2, 2002
-
ARCHIVE Schering-Plough Launches Ono's Leukotriene Antagonist Pranlukast in Mexico
September 2, 2002
-
ARCHIVE Wakamoto: TESTMATE Pylori Antigen EIA before NHI Price Listing
September 2, 2002
-
ARCHIVE Toyama, Taisho to Respect Each Other's Independence
September 2, 2002
-
ARCHIVE Hitachi High-Tech to Market bioMerieux's Blood Coagulation Products
September 2, 2002
-
ARCHIVE MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
September 2, 2002
-
ARCHIVE Fujirebio: Half-year Sales Down 4.8% to \12,209 Mil.
September 2, 2002
-
ARCHIVE General Hospitals' Earnings Up 3 Years in a Row: SWMSC Report
September 2, 2002
-
ARCHIVE Medical Fee Revision Favors Major Dispensing Pharmacies: Nomura Report
September 2, 2002
-
ARCHIVE 70% of Patients Don't Like Substitutive Generics: Survey
September 2, 2002
-
ARCHIVE MEDICAL DEVICE NEWS IN BRIEF
September 2, 2002
-
ARCHIVE Ivermectin, Micafungin Recommended for Approval by CDFS
September 2, 2002
-
ARCHIVE NEW PRODUCTS
September 2, 2002
-
ARCHIVE NHI Price Listing Not Pending for Any More Products
September 2, 2002
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…